Annual report [Section 13 and 15(d), not S-K Item 405]

Document and Entity Information

v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Mar. 25, 2025
Jun. 30, 2024
Cover [Abstract]        
Entity Registrant Name Emmaus Life Sciences, Inc.      
Entity Central Index Key 0000822370      
Document Type 10-K      
Document Period End Date Dec. 31, 2024      
Amendment Flag false      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2024      
Current Fiscal Year End Date --12-31      
Entity File Number 001-35527      
Entity Tax Identification Number 87-0419387      
Entity Incorporation State Country Code DE      
Entity a Well-known Seasoned Issuer No      
Entity a Voluntary Filer No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Entity Shell Company false      
Entity Address, Address Line One 21250 Hawthorne Boulevard      
Entity Address, Address Line Two Suite 800      
Entity Address, City or Town Torrance      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 90503      
City Area Code 310      
Local Phone Number 214‑0065      
Document Annual Report true      
Document Transition Report false      
Entity Common Stock, Shares Outstanding     63,865,571  
Entity Public Float       $ 4,075,413
Title of 12(g) Security Common stock, par value $0.001 per share      
Auditor Name Marcum llp BAKER TILLY US, LLP    
Auditor Location Costa Mesa, California Irvine, California    
Auditor Firm ID 688 23    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Emmaus Life Sciences, Inc. and its subsidiaries (the “Company”) as of December 31, 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ deficit and cash flows for the year in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

The consolidated financial statements of the Company as of and for the year ended December 31, 2023, before the retrospective adjustment described in Notes 2, were audited by other auditors whose report, dated July 2, 2024, expressed an unqualified opinion on those statements. We have audited this retrospective adjustment to the 2023 consolidated financial statements, as reported in the consolidated financial statements as of and for the year ended December 31, 2024, related to the adoption of Accounting Standards Update 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" described in Note 2. In our opinion, such adjustment is appropriate and has been properly applied. We were not engaged to audit, review, or apply any procedures related to the Company’s 2023 consolidated financial statements other than with respect to the adjustment and, accordingly, we do not express an opinion or any other form of assurance on the 2023 consolidated financial statements as a whole.

Opinion on the Financial Statements

We have audited, before the effects of the adjustments to retrospectively apply the changes in presentation of the Company’s segments disclosure described in Note 2, the accompanying consolidated balance sheet of Emmaus Life Sciences, Inc. and its subsidiaries (the “Company”) as of December 31, 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders' deficit, and cash flows, for the year ended December 31, 2023 , and the related notes to the consolidated financial statements (collectively referred to as the “consolidated financial statements”). In our opinion the consolidated financial statements,before the effects of the adjustments to retrospectively apply the changes in presentation of the Company’s segments disclosure described in Note 2,present fairly, in all material respects, the financial position of the Company at December 31, 2023, and the results of its operations and its cash flows for year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

We were not engaged to audit, review, or apply any procedures to the adjustments to retrospectively apply the changes in segment presentation described in Note 2, and accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. The adjustments were audited by other auditors.